Observing the efficacy of azelastine hydrochloride nasal spray combined with budesonide nasal spray in treating persistent allergic rhinitis
10.16066/j.1672-7002.2017.04.004
- VernacularTitle:盐酸氮卓斯汀鼻喷剂联合布地奈德鼻喷剂治疗持续性变应性鼻炎疗效观察
- Author:
Renxia WANG
;
Chunhui ZHANG
- Keywords:
Budesonide;
Administration;
Intranasal;
Rhinitis;
Allergic;
Perennial;
Treatment Outcome;
azelastine hydrochloride nasal spray
- From:
Chinese Archives of Otolaryngology-Head and Neck Surgery
2017;24(4):180-183
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To observe clinical efficacy of azelastine hydrochloride nasal spray plus budesonide nasal spray on persistent allergic rhinitiss(AR). METHODS 120 patients with persistent AR were devided randomly into group A(n=40), group B(n=40) and group C(n=40). Group A were treated with azelastine hydrochloride nasal spray and budesonide nasal spray, group B received only azelastine hydrochloride nasal spray and group C received budesonide nasal spray only, the treatment process were 4 weeks. Clinical efficacy were compared among 3 groups 4 weeks later. RESULTS 1. VAS scores: VAS scores of nasal symptoms in group A were lower than those both in group B and in group C after 4 weeks, the difference were statistically significant(P<0.05); 2. RQLQ scores: RQLQ scores in 3 groups were all significantly improved after 4 weeks, the RQLQ scores of sleep, nonnose/eye symptoms, nasal symptoms and emotions in group A were improved more significantly than those in group B and in group C, the difference were statistically significant(P<0.05); 3. Clinical efficacy: the significant effective rate and the total effective rate were 50.00% and 93.33% in group A, but were 30.00% and 75.00% in group B and 27.50% and 77.50% in group C, the differences between group A and group B or group A and group C were statistically significant(P <0.05). CONCLUSION Azelastine hydrochloride nasal spray plus budesonide nasal spray can rapidly relieve nasal symptoms and improve the life quality of the patients with persistent AR.
